Meningioma
119
47
56
32
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
13 trials with published results (11%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
5.0%
6 terminated out of 119 trials
84.2%
-2.4% vs benchmark
5%
6 trials in Phase 3/4
41%
13 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 32 completed trials
Clinical Trials (119)
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Preoperative Embolization for Highly Vascular Brain Tumors
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
IN10018 in Combination With Dalpiciclib for Progressive Meningiomas
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Embolization for Meningioma
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Selumetinib for NF2-Related Schwannomatosis